ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BIXT Bioxytran Inc (QB)

0.146
0.0207 (16.52%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bioxytran Inc (QB) USOTC:BIXT OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0207 16.52% 0.146 0.1332 0.1597 0.1525 0.1252 0.13 125,155 21:03:30

Form DEL AM - Delaying amendment

21/09/2023 3:53pm

Edgar (US Regulatory)


 

BIOXYTRAN, INC.

75 2nd Ave., Ste 605

Needham, Massachusetts 02494

 

September 21, 2023

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporate Finance

100 F Street N.W.

Washington, D.C. 20549

 

Re:

Bioxytran, Inc. –

Registration Statement on Form S-1, Registration No. 333-274576 Delaying Amendment.

 

Ladies and Gentlemen:

 

Bioxytran, Inc. (the “Registrant”) hereby respectfully submits this corrected Delaying Amendment to the Registrant’s Registration Statement on Form S-1 (File No. 333-274576), together with all exhibits thereto, initially filed on September 19, 2023 (the “Registration Statement”).

 

The Company hereby amends the “Delaying Amendment” language contained in Exhibit 107 to the Registration Statement to read as follows:

 

“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said section 8(a), may determine.”

 

If you have any questions with respect to this matter, please contact Robert J. Burnett, Witherspoon Brajcich McPhee, PLLC at (509) 455-9077.

 

 

Sincerely,

BIOXYTRAN, INC.

   
  /s/ Ola Soderquist
 

Ola Soderquist

Chief Financial Officer

 

 


1 Year Bioxytran (QB) Chart

1 Year Bioxytran (QB) Chart

1 Month Bioxytran (QB) Chart

1 Month Bioxytran (QB) Chart

Your Recent History

Delayed Upgrade Clock